Nivolumab: beside an established treatment under test
112 studies: an approved drug, surgery or radiation is what the study tests. Page 1 of 2. Open to participants first (44), then studies with results posted, then the rest; newest registration first within each.
- PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver CancerRecruitingNCT07884877Phase 2Report a problem
- Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)RecruitingNCT07770100Phase 2Report a problem
- OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic TherapyRecruitingNCT07655583Phase 1Report a problem
- Comparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With MelanomaNot yet recruitingNCT07615881Phase 1/2Report a problem
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)RecruitingNCT07405164Phase 3Report a problem
- 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory TumorsRecruitingNCT07404332Phase 1Report a problem
- Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the LiverRecruitingNCT07364474Not applicableReport a problem
- 125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant TumorsNot yet recruitingNCT07277777Phase 2Report a problem
- Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCCNot yet recruitingNCT07233668Not applicableReport a problem
- Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With ImmunotherapyRecruitingNCT07213557Phase 2Report a problem
- Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept StudyRecruitingNCT07187869Phase 1Report a problem
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and AnxietyRecruitingNCT07174947Phase 2Report a problem
- Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialRecruitingNCT07166406Phase 3Report a problem
- Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant AscitesRecruitingNCT07149090Phase 1/2Report a problem
- Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric AdenocarcinomaRecruitingNCT07000253Phase 2Report a problem
- Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.RecruitingNCT06903312Phase 4Report a problem
- First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.RecruitingNCT06840782Phase 3Report a problem
- Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent ImmunotherapyRecruitingNCT06731270Phase 2Report a problem
- Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder CancerRecruitingNCT06586255Phase 1Report a problem
- Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound HistotripsyRecruitingNCT06524570Phase 1Report a problem
- PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver MetastasesRecruitingNCT06519266Phase 3Report a problem
- Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk MelanomaRecruitingNCT06319196Phase 2Report a problem
- Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal CancerRecruitingNCT06245356Phase 2Report a problem
- Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus ChemotherapyRecruitingNCT06084897Phase 2Report a problem
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerRecruitingNCT06029270Phase 2Report a problem
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyRecruitingNCT05987241Phase 2/3Report a problem
- Naltrexone and Propranolol Combined With ImmunotherapyRecruitingNCT05968690Phase 1Report a problem
- Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC PatientsRecruitingNCT05817903Phase 2Report a problem
- The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN TrialRecruitingNCT05753839Not applicableReport a problem
- mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaRecruitingNCT05677490Phase 3Report a problem
- Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)RecruitingNCT05663775Phase 2Report a problem
- Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerRecruitingNCT05501665Phase 1/2Report a problem
- sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)RecruitingNCT05332002Phase 2Report a problem
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialRecruitingNCT05327686Phase 2Report a problem
- Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine TumorsRecruitingNCT05263050Phase 2Report a problem
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsRecruitingNCT05203172Phase 4Report a problem
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaRecruitingNCT05112601Phase 2Report a problem
- Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With SurgeryRecruitingNCT04991025Phase 2Report a problem
- Nodal Radiation Therapy for Sentinel Lymph Node Positive MelanomaRecruitingNCT04594187Phase 2Report a problem
- A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesRecruitingNCT04511013Phase 2Report a problem
- Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE TrialRecruitingNCT04510597Phase 3Report a problem
- Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor MalignanciesRecruitingNCT04114136Phase 2Report a problem
- Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-TrialRecruitingNCT03977571Not applicableReport a problem
- Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)RecruitingNCT03340129Phase 2Report a problem
- An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung CancerActive, not recruitingNCT05500092Phase 2Results postedReport a problem
- A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver CancerCompletedNCT05337137Phase 1/2Results postedReport a problem
- A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLCTerminatedNCT05144529Phase 2Results postedReport a problem
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTENActive, not recruitingNCT04317105Phase 1/2Results postedReport a problem
- Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)Active, not recruitingNCT04021108Phase 2Results postedReport a problem
- Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaActive, not recruitingNCT03937219Phase 3Results postedReport a problem
- Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck CancerTerminatedNCT03727061Phase 1Results postedReport a problem
- Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab TherapyCompletedNCT03719131Phase 2Results postedReport a problem
- Denosumab + PD-1 in Subjects With Stage III/ IV MelanomaCompletedNCT03620019Phase 2Results postedReport a problem
- Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung CancerCompletedNCT03468985Phase 2Results postedReport a problem
- Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBMActive, not recruitingNCT03452579Phase 2Results postedReport a problem
- Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial CancerCompletedNCT03451331Phase 2Results postedReport a problem
- Priming Immunotherapy in Advanced Disease With RadiationCompletedNCT03313804Phase 2Results postedReport a problem
- A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary CancersTerminatedNCT03115801Phase 2Results postedReport a problem
- Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell CarcinomaActive, not recruitingNCT03071406Phase 2Results postedReport a problem
- An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV MelanomaCompletedNCT03068455Phase 3Results postedReport a problem
- Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney CancerTerminatedNCT03050060Phase 2Results postedReport a problem
- Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung CancerCompletedNCT03035890Not applicableResults postedReport a problem
- A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung CancerTerminatedNCT02967133Phase 2Results postedReport a problem
- Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02823574Phase 2Results postedReport a problem
- Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersActive, not recruitingNCT02785952Phase 3Results postedReport a problem
- Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT02684253Phase 2Results postedReport a problem
- Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02498600Phase 2Results postedReport a problem
- A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)CompletedNCT01716806Phase 2Results postedReport a problem
- Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line TreatmentCompletedNCT07537985Not applicableReport a problem
- PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and SafetyCompletedNCT06991907Not applicableReport a problem
- Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric AdenocarcinomaSuspendedNCT06728657Phase 2Report a problem
- A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)Active, not recruitingNCT06708949Phase 2Report a problem
- Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal CancerSuspendedNCT05904080Phase 2Report a problem
- Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue SarcomaActive, not recruitingNCT05836571Phase 2Report a problem
- Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With ImmunotherapyTerminatedNCT05715229Phase 2Report a problem
- Checkpoint Inhibitors and SBRT for MCRPCCompletedNCT05655715Phase 2Report a problem
- Low-dose Radiotherapy Combined With Conventional Radiotherapy After Immunotherapy FailureStatus unknownNCT05547282Not applicableReport a problem
- Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)WithdrawnNCT05487859Phase 2Report a problem
- Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction CancerActive, not recruitingNCT05476796Phase 2Report a problem
- Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain MetastasesTerminatedNCT05341349Phase 1Report a problem
- HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or FailureStatus unknownNCT05233358Not applicableReport a problem
- Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell CancerActive, not recruitingNCT05148546Phase 2Report a problem
- Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After SurgeryActive, not recruitingNCT05111574Phase 2Report a problem
- PD-1 Antibody Therapy + Infliximab for Metastatic MelanomaActive, not recruitingNCT05034536Phase 2Report a problem
- Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 NegativeActive, not recruitingNCT04929041Phase 2/3Report a problem
- Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial CarcinomaActive, not recruitingNCT04848519Phase 2Report a problem
- Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT04817254Phase 2Report a problem
- Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of MelanomaCompletedNCT04581382Early Phase 1Report a problem
- Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) PatientsActive, not recruitingNCT04159818Phase 2Report a problem
- SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney CancerCompletedNCT04090710Phase 2Report a problem
- A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerActive, not recruitingNCT03873402Phase 3Report a problem
- Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) EffectCompletedNCT03825510Phase 2Report a problem
- Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyActive, not recruitingNCT03793166Phase 3Report a problem
- Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric CancerActive, not recruitingNCT03764553Phase 2Report a problem
- A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint InhibitorsActive, not recruitingNCT03693014Phase 2Report a problem
- Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic MelanomaActive, not recruitingNCT03646617Phase 2Report a problem
- CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid TumorsCompletedNCT03511391Phase 2Report a problem
- SBRT + Immunomodulating Systemic Therapy for Inoperable, Recurrent H&NTerminatedNCT03402737Not applicableReport a problem
- Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung CancerActive, not recruitingNCT03391869Phase 3Report a problem
- Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML PatientsTerminatedNCT03381118Phase 2Report a problem